For over four decades, two competing mechanisms of ligand recognition -conformational selection and induced-fithave dominated our interpretation of protein allostery. Defining the mechanism broadens our understanding of the system and impacts our ability to design effective drugs and new therapeutics. Recent kinetics studies demonstrate that trypsinlike proteases exist in equilibrium between two forms: one fully accessible to substrate (E) and the other with the active site occluded (E*). Analysis of the structural database confirms existence of the E* and E forms and vouches for the allosteric nature of the trypsin fold. Allostery in terms of conformational selection establishes an important paradigm in the protease field and enables protein engineers to expand the repertoire of proteases as therapeutics.
Introduction
Nearly all biological activities of a cell depend on the specific encounter between a ligand and a host target. Understanding the molecular mechanism of how ligands recognize their biological targets and how interactions are regulated remains a central issue to biology, biochemistry, and biophysics [1 ] . The importance extends beyond the basic sciences and affects our ability to design effective drugs and new therapeutics. Knowledge recently emerged from rapid kinetics and structural biology studies on a large class of enzymes, the trypsin-like proteases [2 ] , reveals the unique role that allostery plays in these proteins as the basic mechanism of function and regulation. Protein engineering strategies exploiting the allosteric nature of the trypsin fold show promising new translational opportunities that expand the existing landscape of proteases as therapeutics [3 ] . A critical account of how allostery emerged as the key mechanism of ligand recognition and regulation in trypsin-like proteases is relevant to many other biological systems. We therefore start our discussion with the fundamental properties of the simplest allosteric models of ligand recognition -conformational selection and induced-fit -and present an effective experimental strategy to distinguish between them.
Conformational selection or induced-fit?
In its simplest incarnation, binding of ligand L to its biological target E can be cast in terms of the reaction (Scheme 1).
In Scheme 1 k on (M À1 s
À1
) is the second-order rate constant for ligand binding and k off (s
) is the first-order rate of dissociation of the E:L complex into the parent species E and L. The strength of the interaction is quantified by the equilibrium association constant K a (M
) defined as the ratio k on /k off , or equivalently by the equilibrium dissociation constant K d (M) defined as the inverse of K a , or k off /k on . Scheme 1 provides an important reference point for any discussion of ligand binding, but it offers little information about the mechanism of recognition. What happens when the ligand binds to its target? Is the interaction a rigid body collision between preconfigured species or does it involve conformational changes that optimize binding? In the former case, Scheme 1 adequately describes the kinetics of interaction and the system approaches equilibrium according to an observed rate constant, k obs that increases linearly with [L] . In the latter, the dependence of k obs on [L] is not linear and k obs depends on the nature of conformational changes involved [4 ] . Two limiting cases become of interest as the simplest interpretations of allostery linking binding to conformational transitions [1 ] . In the first case (Scheme 2), the target exists in distinct conformations in equilibrium and the ligand selects the one with optimal fit.
The species E* is added to reflect a pre-existing equilibrium between two forms, E* and E, of which only E can interact with the ligand L. This is the simplest form of the celebrated Monod-Wyman-Changeux model of allosteric transitions [1 ] . In the second case (Scheme 3), the conformation of the target changes after ligand binds to provide an optimal fit. Scheme 3 is the simplest form of the alternative Koshland-Nemethy-Filmer model of allosteric transitions [1 ] . The two mechanisms above can be combined in a more realistic version of ligand binding where a preexisting equilibrium is followed by ligand-induced conformational changes. However, it is quite instructive to note the properties of the simple Schemes 2 and 3 in the kinetics of approach to equilibrium, where invaluable information can be gathered about the nature of conformational transitions involved.
A convenient and widely used assumption is that binding and dissociation steps in Schemes 2 and 3 are fast compared to the conformational changes, that are therefore ratelimiting [4 ] . This is the scenario where the contribution of any conformational change to the kinetics of approach to equilibrium can be best evaluated. The case where conformational changes are rapid compared to binding and dissociation is of little interest because it turns Schemes 2 and 3 into Scheme 1. The kinetic properties of Schemes 2 and 3 in the general case are of great interest, but beyond the scopes of this review and will be discussed elsewhere. Under the assumption of rate-limiting conformational changes, the dependence of k obs on [L] becomes diagnostic of the mechanism involved (Figure 1 ). In the case of 422 Engineering and design 0  1  2  3  4  5  6  7  8  9 10  0  1  2  3  4  5  6  7  8  9 10
Conformational selection and induced-fit. Under the assumption of rate-limiting conformational changes, the dependence of k obs on the ligand concentration is diagnostic of the mechanism of binding, that is, Scheme 2 or Scheme 3. Conformational selection (top left) postulates a pre-existing equilibrium between the E* and E forms, of which only E binds the ligand. The rate of approach to equilibrium, k obs , is an inverse hyperbolic function of the ligand concentration (bottom left, yellow inset) from which the values of k r and k Àr for the E*-E interconversion can be derived directly, along with the value of K d for ligand binding. In this mechanism, the value of k obs decreases with increasing ligand concentration. The induced-fit model (top right) postulates a conformational transition between E*:L and E:L that optimizes binding. The rate of approach to equilibrium, k obs , is an hyperbolic function of the ligand concentration (bottom right, yellow inset) from which the values of k r and k Àr for the E*:L-E:L interconversion can be derived directly, along with the value of K d for ligand binding. In this mechanism, the value of k obs increases with increasing ligand concentration. ], is at variance with well established experimental facts. The proposal is an induced-fit mechanism (Scheme 3) with each species disguised as an ensemble of rapidly interconverting states and therefore predicts an increase of k obs with [L] , contrary to the data in Figure 2 . Replacement of any species with an ensemble of rapidly interconverting states does not change the properties of a kinetic scheme [12, 13] . The proposal also fails to explain how free thrombin (and other proteases), assumed to exist in a continuum of zymogen-like states, crystallizes in the proteinase-like E form (see below).
Trypsin-like proteases are allosteric enzymes obeying conformational selection
Trypsin-like proteases utilize a catalytic triad for activity, composed of the highly conserved residues H57, D102, and S195 (chymotrypsinogen numbering). Catalysis is assisted by several structural determinants surrounding the active site [14] . Residue 189 at the bottom of the primary specificity pocket engages the substrate residue at the site of cleavage. The oxyanion hole defined by the backbone N atoms of S195 and G193 stabilizes the developing partial charge on the tetrahedral intermediate during the catalytic cycle. Residues in the 215-217 segment flanking the active site provide additional recognition sites for substrate residues immediately upstream of the peptide bond to be cleaved.
Activity in trypsin-like proteases ensues via a common mechanism that involves the irreversible processing of an inactive zymogen precursor. The zymogen is proteolytically cut between residues 15 and 16 in all members of the family to generate a new N-terminus that relocates inside the protein to stabilize the architecture of the active site via an ion-pair with D194 [14] . The zymogen to protease conversion is commonly interpreted as an irreversible transition from an inactive to active form and is a particularly useful paradigm to understand the initiation, progression, and amplification of enzyme cascades, where each component acts as a substrate in the inactive zymogen form in one step and as an active enzyme in the 
subsequent step [15 ] . However, extreme variation in catalytic activity is detected among different proteases after conversion from the zymogen. Some enzymes such as trypsin and thrombin are highly active toward most physiological substrates, but others such as complement factor B and clotting factor VIIa require specific cofactors to manifest catalytic competence. A reasonable explanation is that cofactor-assisted catalysis is typically required of enzymes that assume an inactive conformation after the irreversible transition from the zymogen form. The cofactor corrects this molecular defect by switching the enzyme to its active conformation as seen in the complement [16 ] and coagulation [17 ] cascades, which raises an issue of great mechanistic significance. Are the two conformations of the protease, inactive and active, in pre-existing equilibrium or is the protease inactive until the cofactor induces a transition to the active conformation? Kinetics unequivocally provide evidence of the E*-E equilibrium (Figure 2 ), so the logical conclusion is to associate E* in Scheme 2 with the inactive form of the protease and E with the active form. In this scenario, trypsin-like proteases are allosteric enzymes that exist in two forms in equilibrium, E* (inactive) and E (active), after the irreversible conversion from zymogen. The two conformations have distinct functional properties and conformational selection is the single most important factor defining the level of biological activity. When the protease is preferentially stabilized in the E form, it displays full activity and is ready for action as soon as it is irreversibly converted from the zymogen. On the other hand, proteases preferentially stabilized in the E* form remain poorly active even after the irreversible conversion from zymogen has taken place. In this case, binding of a cofactor helps switch E* to the E form to elicit activity. Structural biology strongly supports conformational selection as a key feature of the trypsin fold [18 ] .
The E*-E equilibrium: role of the 215-217 segment (Figure 3 ). In the E form, the 215-217 segment leaves access to the active site wide open. In the E* form, the segment collapses into the active site and precludes substrate binding. The D216G mutant of aI-tryptase crystallizes in the free form with the 215-217 segment in equilibrium between the E and E* conformations in a 3:1 ratio [20 ] . Thrombin crystallizes in the E or E* forms depending on solution conditions [6 ] . Alternative conformations of the 215-217 segment are not a prerogative The E* and E forms. Ribbon representation of the structures of the thrombin mutant Y225P in the E (3S7K) and E* (3S7H) forms. This mutant is devoid of Na + binding and carries P225 as seen in the vast majority of trypsin-like proteases. The two forms are in equilibrium when the enzyme is free in solution, according to Scheme 2 validated by rapid kinetics data (Figure 2 ). In the E* form, the side chain of W215 and the entire 215-217 segment collapse into the active site. In the E form, W215 moves back 10.9 Å and the 215-217 segment moves 6.6 Å to make the active site accessible to substrate. The rmsd between the two forms is 0.345 Å . Relevant residues are labeled and rendered as sticks. The drastic conformational rearrangement linked to the E*-E interconversion is illustrated by a movie of the linear interpolation of the crystal structures 3S7K and 3S7H (inset).
of the protease and are also documented in the zymogen. A high resolution structure of chymotrypsinogen was the first to reveal two distinct conformations of the 215-217 segment in two molecules in the asymmetric unit [21 ] , consistent with the E*-E equilibrium. More recently, crystals of prethrombin-2 harvested from the same well were found to assume alternative conformations of the 215-217 segment [22 ] .
The foregoing examples offer unequivocal evidence of the existence of two alternative conformations for the 215-217 segment in the same protein scaffold, a prerequisite of conformational selection, and align structural observations with kinetic evidence (Figure 2) . Inspection of the entire structural database documents E* and E as a basic property of the trypsin fold. When all structures belonging to the Trypsin Pfam (PF00089, 1382 total) are
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Collapsed 36, 37] for which the first evidence of collapse of W215 in the active site was reported [38] . Importantly, both thrombin and factor D switch to the E form upon binding of allosteric effectors [29 ] or cofactors [16 ], consistent with the E*-E equilibrium being at the basis of their function. Other enzymes crystallizing in the E* form are prostate specific antigen [39] , chymotrypsin [40, 41] , aI-tryptase [20 ,42] , tonin [43] , hepatocyte growth factor activator [44] , the prophenoloxidase activating factor II [45] , and prostasin [46, 47] . Proteases crystallizing in the E form include complement factor C1r [48] Zymogen   1dst  1dsu  1hfd  2xw9  2xwa  1gvz  1kdq  2jet  1lto  2f9o  1rd3  1tq0  3ee0  2gp9  3bei  3gic  3jz2  3s7h  3edx  3hk3  3hk6  1ton  1ybw  2b9I  3dfj  3e1x  1md8  1mh0  1sgi  2pgb  3qgn  3s7k  2ocv  1npm  2f9o  2g51  2g52  2i6q  2i6s  2odp  2odq  1chg  1ex3  2cga  1ddj  1qrz  1fdp  1gvI  1md7  1mza  1mzd  1sgf  3nxp  3sqe  3sqh  1tgb  1tgn  1zjk  2cga  2f83  2ok5 Current Opinion in Structural Biology
Active site accessibility in the protease and zymogen. Accessibility of the active site for all trypsin-like proteases and zymogens in the free form (Table  1) , calculated in terms of the overlap with PPACK in the reference structure 1SHH of thrombin and expressed as percentage of the total volume of inhibitor [18 ] . The complete list of structures meeting the criteria for analysis is provided in Table 1 . The analysis identifies two groups: one with considerable blockage of the active site where overlap with the volume to be occupied by PPACK is on the average 40% (protease) or 27% (zymogen) of total volume (red bars), and the other with negligible or no overlap averaging 0.3% (protease or zymogen) of total volume (green bars). The dichotomous distribution supports existence of an equilibrium between mutually exclusive, collapsed (E*) and open (E) forms in both the zymogen and protease.
[21 , 56, 57] , plasminogen [58, 59] in which the steric hindrance is partially relieved upon binding of streptokinase [27], complement profactor D [60] , prokallikrein 6 [61] , complement profactor C1r [48] , progranzyme K [62] , the inactive a-subunit of the 7S nerve growth factor [63] , prethrombin-1 [64] , and prethrombin-2 [22 ] . Few zymogens assume the E conformation. They are trypsinogen [65, 66] , the zymogen of MASP-2 [67] , chymotrypsinogen [21 ] , coagulation factor XI [68] , and complement profactor B [69] . These structures challenge the paradigm of the zymogen being inactive.
Exploiting the E*-E equilibrium in protein engineering
Conformational selection embodied by the E*-E equilibrium provides a mechanism to manipulate protease activity for therapeutic purposes. When the equilibrium is shifted to the E* form by synthetic molecules or protein engineering, activity of the enzyme is greatly compromised. Allosteric inhibitors of trypsin-like proteases have been reported for factor VIIa [70 ] and thrombin [71 ] . Their mechanism of action is intriguing because it does not target the active site of the enzyme, yet produces effective perturbation of catalytic activity toward natural substrates. This may prove advantageous in reducing unwanted side effects due to cross reactivity with cognate proteases. Protein engineering of trypsin-like proteases aimed at exploiting the E*-E equilibrium is even more promising for therapeutic applications. Poorly active variants of clotting factor Xa have been developed to bypass the intrinsic pathway of coagulation and ameliorate hemophilia conditions [72 ] . In this case, the engineered factor Xa variant likely exists in the E* form until binding of the cofactor Va restores activity by converting the mutant into the active E form. This scenario also applies to the successful conversion of thrombin into an anticoagulant [73 ] . When thrombin is generated from prothrombin in response to a vascular lesion, it carries out a procoagulant role by cleaving fibrinogen and promoting formation of a fibrin clot and a prothrombotic role by promoting platelet aggregation via activation of PAR1. These functions are carried out by the high activity E form and do not require a macromolecular cofactor. At the level of the microcirculation, thrombin is hijacked by the endothelial receptor thrombomodulin that shuts down both the procoagulant and prothrombotic activities while enhancing specificity toward the anticoagulant protein C. Activated protein C generated by the thrombin-thrombomodulin complex acts as a potent anticoagulant and cytoprotective agent. A thrombin mutant engineered for exclusive activity toward protein C and devoid of activity toward fibrinogen and the platelet receptor PAR1 could represent an innovative and potentially powerful tool to achieve anticoagulation without disruption of the hemostatic balance. Proof-of-principle that such a strategy could benefit the treatment of thrombotic disorders has come from in vivo studies in non-human primates [74 ,75 ] . Specifically, the anticoagulant thrombin mutant W215A/E217A has emerged as the most promising candidate with antithrombotic and cytoprotective effects more efficacious than the direct administration of activated protein C and safer than the administration of low molecular weight heparins [73 ] . The single amino acid replacement E217K [76] and deletion of the autolysis loop [28 ] also produce a notable anticoagulant profile. The mechanism of action of these mutants is directly Crystal structures of the anticoagulant thrombin mutants W215A/E217A (a, 1TQ0), D146-149e (b, 3GIC) and E217K (c, 1RD3). Structures are overlaid with the reference structure 1SHH of thrombin bound to PPACK (green), where only PPACK is shown for clarity. The 215-217 segment carrying the W215A/E217A mutation (a, 1TQ0) collapses into the active site and clashes with the side chain of Arg at the P1 position of PPACK occluding 29% of the total volume of the inhibitor. In the case of the D146-149e loopless mutation (b, 3GIC), the entire 215-217 moves into the active site and occludes 48% of the volume of PPACK. Overlap for the E217K mutant (c, 1RD3) is 37% (see also Figure 4 ). The structures of W215A/E217A, D146-149e and E217K offer substantial insight into the mechanism of action of these mutants and show how thrombin can be turned into an anticoagulant with sitedirected mutations that stabilize the E* form.
related to perturbation of the E*-E equilibrium. The mutation stabilizes the E* form [28 ] , thereby making activity toward fibrinogen and PAR1 vanishingly small, but transition to the active E form ensues upon a concerted action of thrombomodulin and protein C that cannot be reproduced by the procoagulant substrates. Indeed, crystal structures of W215A/E217A [33] , the loopless [28 ] , and E217K [32] mutants reveal a conformation for the free enzyme where the 215-217 segment is collapsed ( Figure 5) as seen in the E* form.
The E*-E equilibrium offers ways to increase the activity of the enzyme by stabilizing the E form, as shown recently for thrombin [77] . Stabilization of E in the zymogen form may promote activation. Natural examples of cofactorinduced activation of the zymogen are the interaction of streptokinase with plasminogen [27] or staphylocoagulase with prothrombin [78] . The activation is non-proteolytic and involves an allosteric shift in the conformation of the zymogen toward a state that resembles the E form of the protease. This strategy has recently been exploited in other systems with synthetic molecules. Hepatocyte growth factor binds to its target receptor tyrosine kinase, Met, as a single-chain form or as a cleaved two-chain disulfide-linked heterodimer that stimulates Met signaling [79 ] . Peptides corresponding to the first 7-10 residues of the cleaved Nterminus of the b-chain stimulate Met phosphorylation by the zymogen (single-chain) to levels that are 25% of those stimulated by the two-chain form. Small molecule activators of zymogens have been reported recently for the apoptotic procaspase-3 and procaspase-6 [80 ] as surprisingly inducers of autoproteolytic activation by stabilization of a conformation that is both more active and more susceptible to intermolecular proteolysis. Even for this different class of proteolytic enzymes, an allosteric E*-E equilibrium can be invoked to explain transition to a more competent state that possibly triggers autoproteolysis.
Conclusions and future directions
Kinetic and structural data make a solid case for the allosteric nature of trypsin-like proteases. The importance of allostery has long been recognized in a few members of this large family of enzymes [21 ] . The field is now mature for a broader appreciation of conformational selection as the embodiment of allostery in the trypsin fold. The conclusion is supported by an increasing number of crystal structures (Figure 4 ) and unequivocal kinetic signatures (Figure 2) . The pre-existing E*-E equilibrium is the defining property of these enzymes, with far reaching consequences on our understanding of their structure, function and regulation. The E*-E equilibrium also offers a conceptual framework for the development of new therapeutic strategies aimed at inhibiting or activating the enzyme. The effects can be achieved by small molecules directed at one of the alternative conformations, or by protein engineering strategies aimed at tipping the equilibrium with site-directed mutagenesis. Moving forward, efforts should be devoted to the design and screening of small molecules that target selectively the E* or E form. Protein engineering of proteases and zymogens that take advantage of the E*-E equilibrium will undoubtedly expand the landscape of proteases as therapeutics [3 ] .
Challenges remain for the structural biologists and enzymologists as they seek evidence of a pre-existing equilibrium between alternative conformations in proteases where such evidence is not currently available. Efforts should be devoted to trap the E*-E equilibrium in solution using rapid kinetics and NMR. Maltose-binding protein offers a relevant example where alternative conformations in pre-existing equilibrium have been detected by NMR [81] . However, important lessons should be learned from X-ray structural biology and its successes in trapping the E* and E forms in the same protein scaffold [6 ] or even the same protein crystal [20 ,21 ] . Most strikingly, alternative conformations have been detected in different crystals harvested from the same crystallization well [22 ] . These are significant developments when we consider that structural validation of conformational selection, that is, a pre-existing equilibrium between alternative conformations, has long remained a challenge even for textbook examples of allosteric proteins [1 ].
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